Supernus Pharmaceuticals, Inc. (SUPN)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
21.83-0.24 (-1.09%)
At close: 4:00 PM EDT
People also watch:
SCMPPCRXRPTPOMERIRWD
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open22.09
Prev Close22.07
Bid20.82 x 1000
Ask22.00 x 100
Day's Range21.48 - 22.09
52wk Range9.51 - 24.00
1y Target EstN/A
Market Cap1.08B
P/E Ratio (ttm)44.55
Beta1.50
Volume268,168
Avg Vol (3m)524,293
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Supernus Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SUPN-US : August 29, 2016
    Capital Cube17 hours ago

    Supernus Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SUPN-US : August 29, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Supernus Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Investopedia7 days ago

    Smaller Biotechs Surging to New Highs

    Small- and mid-cap biotechs are attracting healthy buying interest and setting off bullish divergences that support higher prices into year-end.

  • Supernus' Trokendi XR Gets FDA Nod for Migraine in Adults
    Zacks8 days ago

    Supernus' Trokendi XR Gets FDA Nod for Migraine in Adults

    Supernus Pharmaceuticals, Inc. (SUPN) announced that the FDA has granted a tentative approval to the company's sNDA for a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults.